DXCM vs STE
Dexcom and STERIS plc, both Healthcare
Dexcom is the larger company at $28B against $20B. On trailing earnings STE is the cheaper of the two at a P/E of 26.2 against 33.4, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +11% against -14% for STE. The RyuScore puts DXCM ahead, 73 against 69 out of 100.
| Figure | DXCM | STE |
|---|---|---|
| Last close | $84.10 | $214 |
| Market cap | $28B | $20B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.4 | 26.2 |
| Dividend yield | n/a | 1.2% |
| 1-year return | +11% | -14% |
| 5-year return | -38% | +6.5% |
| RyuScoresector-relative, 1–10 | 73/100 | 69/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
STERIS plc
Revenue of $1.5B in Q1 2027, net income $200M. Its largest reported line is Healthcare, 70% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.